Drupal.behaviors.print = function(context) {window.print();window.close();}>
MDx/CDx Focus: Phase III Adcetris Trial in Hodgkin Lymphoma; FDA Priority Review for Roche's T-DM1
November 07, 2012
MDx/CDx Focus: Phase III Adcetris Trial in Hodgkin Lymphoma; FDA Priority Review for Roche's T-DM1
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
MDx/CDx Focus: AssureRx Launches ADHD PGx Test; Adcetris Phase III Study in CD-30 Lymphoma; CardioDx
May 9, 2012 / Pharmacogenomics Reporter
FDA Approves Genentech's Antibody-Drug Conjugate, Marking Third Rx for HER2-Targeted Breast Cancer
February 27, 2013 / Pharmacogenomics Reporter
MDx/CDx Focus: Studies Reported At ESMO on Roche's Herceptin, T-DM1, Pfizer's Xalkori
October 3, 2012 / Pharmacogenomics Reporter
During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter
Genentech Planning Regulatory Filing This Year for New Personalized Rx for Advanced Breast Cancer
June 6, 2012 / Pharmacogenomics Reporter